ASH 2024 | Unmet needs in the management of Castleman disease
Joshua Brandstadter, MD, PhD, University of Pennsylvania, Philadelphia, PA, comments on the challenges in managing Castleman disease, a rare inflammatory disorder characterized by enlarged lymph nodes. He notes that patients often face delayed diagnosis and limited treatment options, with only one FDA-approved medication. Dr Brandstadter highlights the need for alternative treatment strategies. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Castleman disease is a rare inflammatory disorder that presents with enlarged lymph nodes with a certain histologic appearance. Like other patients who have rare diseases, patients with Castleman routinely suffer from the ignominies of a delayed diagnosis, questions of whether or not they can get the diagnosis at all, and whether they can get a prompt and correct diagnosis. What’s more, Castleman disease patients only have one FDA-approved medication for their treatment if they have the idiopathic multicentric variety of Castleman disease that can present with a systemic inflammatory syndrome that can potentially cause multi-organ system failure, ICU admissions, and potentially death...
Castleman disease is a rare inflammatory disorder that presents with enlarged lymph nodes with a certain histologic appearance. Like other patients who have rare diseases, patients with Castleman routinely suffer from the ignominies of a delayed diagnosis, questions of whether or not they can get the diagnosis at all, and whether they can get a prompt and correct diagnosis. What’s more, Castleman disease patients only have one FDA-approved medication for their treatment if they have the idiopathic multicentric variety of Castleman disease that can present with a systemic inflammatory syndrome that can potentially cause multi-organ system failure, ICU admissions, and potentially death. And that one FDA-approved treatment is siltuximab, an IL-6 blocker. But about half to maybe more than half of patients will not respond to that one FDA-approved therapy. So the second major challenge that Castleman disease patients face is what to do for patients whose disease does not respond to siltuximab or IL-6 antagonism.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
